Succinobucol‐eluting stents increase neointimal thickening and peri‐strut inflammation in a porcine coronary model. Issue 4 (8th November 2012)

• Record Type: Journal Article
• Authors: Watt, Jonathan; Kennedy, Simon; McCormick, Christopher; Agbani, Ejaife O.; McPhaden, Allan; Mullen, Alexander; Czudaj, Peter; Behnisch, Boris; Wadsworth, Roger M.; Oldroyd, Keith G.
• Is Part Of: Catheterization and cardiovascular interventions. Volume 81:Issue 4(2013:Mar. 01)
• Page Start: 698
• Page End: 708
• Publication Date: 2012-11-08
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.24473
• Languages: English
• ISSNs: 1522-1946

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ccd24473-sec-0001" sec-type="section"> <title>Objective</title> <p>The aim of this study was to assess the efficacy of stent‐based delivery of succinobucol alone and in combination with rapamycin in a porcine coronary model. <italic>Background</italic>: Current drugs and polymers used to coat coronary stents remain suboptimal in terms of long term efficacy and safety. Succinobucol is a novel derivative of probucol with improved antioxidant and anti‐inflammatory properties.</p> </sec> <sec id="ccd24473-sec-0002" sec-type="section"> <title>Methods</title> <p>Polymer‐free Yukon stents were coated with 1% succinobucol (SucES), 2% rapamycin (RES), or 1% succinobucol plus 2% rapamycin solutions (SucRES) and compared with a bare metal stent (BMS).</p> </sec> <sec id="ccd24473-sec-0003" sec-type="section"> <title>Results</title> <p>The <italic>in vivo</italic> release profile of SucES indicated drug release up to 28 days (60% drug released at 7 days); 41 stents (BMS, <italic>n</italic> = 11; SucES, <italic>n</italic> =10; RES, <italic>n</italic> = 10; SucRES, <italic>n</italic> = 10) were implanted in the coronary arteries of 17 pigs. After 28 days, mean neointimal thickness was 0.31 ± 0.14 mm for BMS, 0.51 ± 0.14 mm for SucES, 0.19 ± 0.11 mm for RES, and 0.36 ± 0.17 mm for SucRES (<italic>P</italic> < 0.05 for SucES vs. BMS). SucES increased inflammation and fibrin deposition compared with BMS (<italic>P</italic> < 0.05), whereas RES reduced inflammation compared with BMS (<italic>P</italic> < 0.05).</p> </sec> <sec id="ccd24473-sec-0004" sec-type="section"> <title>Conclusion</title> <p>In this model, stent‐based delivery of 1% succinobucol using a polymer‐free stent platform increased neointimal formation and inflammation following coronary stenting. © 2012 Wiley Periodicals, Inc.</p> </sec> </abstract>